Imbruvica — CareFirst (Caremark)
Marginal zone lymphoma (MZL) including extranodal (gastric or nongastric MALT), nodal, or splenic types
Initial criteria
- Member has received at least one prior therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on Imbruvica
Approval duration
12 months